Will Biogen and Eisai keep pursuing Alzheimer's in tandem?

Will Biogen and Eisai push forward with their Alzheimer’s disease partnership? The answer’s unclear, in the wake of the high-stakes aducanumab failure. 

Eisai announced Friday that it plans to press ahead with another Alzheimer’s candidate, called BAN2401, which is also part of its Biogen partnership. 

But is Biogen along for the ride? According to STAT’s Adam Feuerstein, the company had a notably cautious reply. 

Read more.